GO
| HSI1 | 25,797.85 | +122.67 | 272.17B |
| HSCEI1 | 8,639.96 | +41.99 | 89.50B |
| Back Zoom + Zoom - Block Traded | |
|
2026-05-18 14:18:16 Local pharmacy chain Lung Fung Group has passed its listing hearing and plans to list on the Main Board, with DBS as the sole sponsor. According to the prospectus and Frost & Sullivan, in 2024, by retail sales value, the Group ranked second among beauty products, healthcare products and pharmaceutical retailers in Hong Kong, with a market share of 5.8%. By retail sales value, the Company was the largest pharmaceutical retailer in Hong Kong with a market share of 5.2%. By revenue, it was also the second-largest pharmaceutical and healthcare products retailer in Hong Kong, with a market share of approximately 4.2%. For the first eight months of FY2026 ended late November last year, total revenue was approximately HKD2.035 billion, up 34.7% YoY, while profit for the period was approximately HKD148 million, up 85.8% YoY. The Company expects to distribute annual dividends after listing of not less than 50% of profit available for distribution to shareholders. The Company currently operates 31 stores in Hong Kong and plans to open up to 17 to 18 new retail stores over the next three years. (da/u)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |